With a $29 million National Institutes of Health grant, Rutgers Institute for Translational Medicine and Science will advance clinical research into patient care and treatment more quickly. With partners like Princeton University and NJIT in this statewide collaboration, Rutgers will enable research teams, patient advocacy organizations and members of the community to tackle systemwide scientific and operational challenges.
Rutgers Cancer Institute of New Jersey celebrates its re-designation as the state’s only Comprehensive Cancer Center by the National Cancer Institute, a prestigious recognition awarded to centers with the highest excellence in cancer research and the ability to translate these discoveries to clinical care. Accompanied by a $15.1 million grant, the award enables enhanced collaborations with pharmaceutical and biotechnology companies in areas such as clinical trials.
Rutgers’ new Entrepreneur-in-Residence Program harnesses the experience of seasoned entrepreneurs to create startups around promising university technologies and intellectual property.
Rutgers and Horizon Discovery, a global leader in gene editing, formed an exclusive strategic partnership to further develop and commercialize a novel gene editing technology, known as base editing, that builds on CRISPR to treat genetic diseases.
The latest Rutgers startup – Simsi Inc. – commercializes Risk Terrain Modeling technology, an evidence-based Geo-spatial risk analysis and diagnostic platform for crime prevention and public safety, that is used by police to deploy resources and prevent crime.
If you’re looking to collaborate on research, find an expert, commercialize a Rutgers technology, or build and develop your workforce, the new Rutgers Corporate Engagement Center is your front door to the university. Connect with us – we’ll bring the right people to the conversation.
Contact: Sacha Patera, PhD, Associate Vice President
Email: [email protected]
Call: 848-932-4484